Evidence map›Paper›PMID 39127737›Full record

ArticleJournal of nanobiotechnology2024

A bioinspired supramolecular nanoprodrug for precision therapy of B-cell non-Hodgkin's lymphoma.

Qixiong Zhang, Yuhan Tian, Yanrui Yang, Qiuying Huang, Haibo Feng, Rui Zeng, Shanshan Li

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Qixiong ZhangDepartment of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Academy of Medical Science & Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, 610072, China. qixiongzhang@outlook.com.
Yuhan TianCollege of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai-Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China.
Yanrui YangCollege of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai-Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China.
Qiuying HuangCollege of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai-Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China.
Haibo FengCollege of Animal & Veterinary Sciences, Southwest Minzu University, Chengdu, 610041, China.
Rui ZengCollege of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai-Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China.
Shanshan LiCollege of Pharmacy, Key Laboratory of Research and Application of Ethnic Medicine Processing and Preparation on the Qinghai-Tibet Plateau, Southwest Minzu University, Chengdu, 610041, China. sslscu2009@163.com.

Funding

Chengdu Municipal Science and Technology Program 2022YF05-01626-SNNational Natural Science Foundation of China 82204304Natural Science Foundation of Sichuan Province 2023NSFSC1678Natural Science Foundation of Sichuan Province 2024NSFSC0197Personalized Drug Therapy Key Laboratory of Sichuan Province 2022YB01Scientific and Technological Innovation Team for Qinghai-Tibetan Plateau Research in Southwest Minzu University 2024CXTD15Southwest Minzu University RQD2022033Youth Innovation Project of Sichuan Medical Association Q22006
6 · The paper itself

Abstract

Fludarabine (FA) is still considered as a first-line chemotherapy drug for hematological tumors related to B lymphocytes. However, it is worth noting that the non-specific distribution and non-different cytotoxicity of FA may lead to irreversible consequences such as central nervous system damage such as blindness, coma, and even death. Therefore, it is very important to develop a system to targeting delivery FA. In preliminary studies, it was found that B lymphoma cells would specific highly expressing the sialic acid-binding immunoglobulin-like lectin 2 (known as CD22). Inspired by the specific recognition of sialic acid residues and CD22, we have developed a supramolecular prodrug based on polysialic acid, an endogenous biomacromolecule, achieving targeted-therapy of B-cell non-Hodgkin's lymphoma (B-NHL). Specifically, the prepared hydrophobic reactive oxygen species-responsive FA dimeric prodrug (F

Indexed as

Lymphoma, B-CellProdrugsAnimalsAntineoplastic AgentsCell Line, TumorDrug Delivery SystemsHumansLymphoma, Non-HodgkinMiceMice, Inbred BALB CNanoparticlesPrecision MedicineReactive Oxygen SpeciesSialic Acid Binding Ig-like Lectin 2Sialic AcidsAntineoplastic Agentspolysialic acidProdrugsReactive Oxygen SpeciesSialic Acid Binding Ig-like Lectin 2Sialic AcidsB-cell lymphomaFludarabinePolysialic acidSupramolecular nanoprodrugWatson–Crick base pairing

Identifiers

PMID39127737
PMCPMC11316380

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.